Ascendis Pharma A/S
ASND
178 hedge funds and large institutions have $7.27B invested in Ascendis Pharma A/S in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 64 increasing their positions, 61 reducing their positions, and 23 closing their positions.
54% more call options, than puts
Call options by funds: $48M | Put options by funds: $31.1M
30% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 23
14% more funds holding in top 10
Funds holding in top 10: 14 → 16 (+2)
6.32% more ownership
Funds ownership: 102.55% → 108.87% (+6.3%)
3% more funds holding
Funds holding: 172 → 178 (+6)
5% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 61
7% less capital invested
Capital invested by funds: $7.85B → $7.27B (-$582M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$197M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$68.9M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$31.6M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$28.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$48.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.1M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$13M |
| 4 |
SCM
Spyglass Capital Management
San Francisco,
California
|
-$12.5M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$10.8M |
ASND Hedge Fund Activity: Q1 2022 in Review
178 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2022, worth a combined $7.27B — down 7.4% from $7.85B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ASND positions and 23 closed out — a net gain of 7 holders — while 64 added to existing stakes and 61 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $197M. The largest seller was Eventide Asset Management, cutting an estimated $48.6M.
- 178 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2022, up from 172 in Q4 2021.
- Funds reported $7.27B of Ascendis Pharma A/S stock for Q1 2022, down 7.4% quarter-over-quarter.
- 30 funds opened new Ascendis Pharma A/S positions in Q1 2022 and 23 closed out, a net change of +7 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2022 was Goldman Sachs, an estimated $197M added.
- The largest Ascendis Pharma A/S seller in Q1 2022 was Eventide Asset Management, an estimated $48.6M sold.
Based on aggregated 13F filings for Q1 2022.